The first and only anti-VEGF proven effective and safe for diabetic retinopathy (DR) with and without DME 1,13

Choose LUCENTIS to treat diabetic retinopathy

LUCENTIS demonstrates significant regression in retinopathy across DR subtypes and is indicated to treat DR with or without DME. 1

PATIENT CASES 9:

Severe NPDR

Moderate PDR

High-Risk PDR

ETDRS, Early Treatment Diabetic Retinopathy Scale; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; VEGF, vascular endothelial growth factor.

Resources
Resources for your patients.
LUCENTIS Direct
Simple, personalized ordering.
LUCENTIS Co-pay Card Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Genentech Access Solutions is your resource for access and reimbursement support services.